secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009820
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports early PRs for ERAS-0015 at 8 mg QD; Phase 1 dose escalation faster than expected
--------------------------------------------------------------------------------

- ERAS-0015 AURORAS-1 trial: two confirmed PRs and one unconfirmed PR in patients with different tumor types and RAS mutations at 8 mg QD.
- No dose-limiting toxicities; predominantly low-grade AEs; linear PK across all dose levels evaluated (data cutoff Jan 7, 2026).
- Initial Phase 1 monotherapy data for ERAS-0015 planned for H1 2026; expansion/combination cohorts start H2 2026.
- ERAS-4001 BOREALIS-1 Phase 1 dose escalation advancing as expected; initial monotherapy data planned H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526009820/0001193125-26-009820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526009820/eras-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer